Zhang Qicheng, Xu Ke
Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
Genes Dis. 2022 Jan 29;10(2):495-504. doi: 10.1016/j.gendis.2021.12.017. eCollection 2023 Mar.
N-methyladenosine (mA) modification is found the most prevalent and abundant post-transcriptional mRNA modification in eukaryotic cells. It regulates almost all stages of RNA life cycle including splicing, translocation, stability, decay and translation. As a dynamic and reversible process, mA modification is catalyzed by the RNA methyltransferases ('writers'), removed by the demethylases ('erasers'), and interacts with mA-binding proteins ('readers'). Recent studies have revealed that these mA modification regulators are frequently expressed aberrantly in various types of cancer, and involved in cell proliferation, differentiation, metabolism, particularly, in tumorigenesis and tumor progression through diverse mechanisms. In this review, the mA modification process and its regulatory functions in lung cancer are summarized. Furthermore, the research progress in the inhibitor development of mA modification, and the potential of targeting mA modifying proteins for clinical application are discussed.
N6-甲基腺苷（m6A）修饰是真核细胞中最普遍、最丰富的转录后mRNA修饰。它几乎调控RNA生命周期的所有阶段，包括剪接、转运、稳定性、降解和翻译。作为一个动态可逆的过程，m6A修饰由RNA甲基转移酶（“书写者”）催化，由去甲基化酶（“擦除者”）去除，并与m6A结合蛋白（“阅读者”）相互作用。最近的研究表明，这些m6A修饰调节因子在各种类型的癌症中经常异常表达，并通过多种机制参与细胞增殖、分化、代谢，特别是肿瘤发生和肿瘤进展。在这篇综述中，总结了m6A修饰过程及其在肺癌中的调控功能。此外，还讨论了m6A修饰抑制剂开发的研究进展以及靶向m6A修饰蛋白的临床应用潜力。
